Prof. Dr. Meral Beksaç

P-068: Haplotypes rich in activating killer-cell immnuglobulin-like receptor genes are associated with delay on age of myeloma onset

Clinical Lymphoma Myeloma & Leukemia, 2021

DOI 10.1016/s2152-2650(21)02202-3 Source : OpenAlex

P-038: Postinduction minimal residual disease (MRD) within stem cell graft (gMRD) correlates with marrow MRD (mMRD) and progression free survival (PFS) following autologous stem cell transplantation

Clinical Lymphoma Myeloma & Leukemia, 2021

DOI 10.1016/s2152-2650(21)02172-8 Source : OpenAlex

Poster: MM-130: Updates from ICARIA-MM, a Phase 3 Study of Isatuximab (Isa) Plus Pomalidomide and Low-Dose Dexamethasone (Pd) vs Pd in Relapsed and Refractory Multiple Myeloma (RRMM)

Clinical Lymphoma Myeloma & Leukemia, 2021

DOI 10.1016/s2152-2650(21)01572-x Source : OpenAlex

Early Access Program Results From Turkey and a Literature Review on Daratumumab Monotherapy Among Heavily Pretreated Patients With Relapsed/Refractory Myeloma

Clinical Lymphoma Myeloma & Leukemia, 2020

DOI 10.1016/j.clml.2020.02.017 PMID 32482539 6 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

Ibrutinib As a Promising Treatment for Heavily Pretreated Waldenström Macroglobulinemia: A Real World Data

Blood, 2020

DOI 10.1182/blood-2020-138899 Source : OpenAlex

Bir Nakil Merkezinin 11 Yıllık Allojeneik Kök Hücre Nakli Deneyimi

LLM Dergi, 2020

DOI 10.5578/llm.70231 Texte intégral en libre accèsSource : ORCID

Miyelodisplastik Sendrom Hastalarının Akan Hücre Ölçer ile Yapılan Ogata Skorlaması Yoluyla Değerlendirilmesi: Pilot Çalışma

LLM Dergi, 2020

DOI 10.5578/llm.70136 Texte intégral en libre accèsSource : ORCID

Allogeneic Stem Cell Transplantation in Myelodysplastic Syndrome

Journal of Ankara University Faculty of Medicine, 2020

DOI 10.4274/atfm.galenos.2020.65365 Texte intégral en libre accèsSource : ORCID

25 Years of Autologous Transplantation for Myeloma in Ebmt Centres - Changing Practice Patterns

Bone Marrow Transplantation, 2020

Source : ORCID

A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Isatuximab, Pomalidomide, and Low-Dose Dexamethasone Versus Pomalidomide and Low-Dose Dexamethasone in Patients with Relapsed / Multiple Myeloma Refractory (RRMM)

Oncology Research and Treatment, 2020

Source : ORCID

A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: Analysis of parameters that improve outcome

Haematologica, 2020

DOI 10.3324/haematol.2019.219295 PMID 31278209 65 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

A real-world single-center retrospective study on efficacy and safety of pegylated interferon alpha-2a in epatients with myeloproliferative neoplasm

Journal of Clinical Oncology, 2020

Source : ORCID

Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma

Annals of Hematology, 2020

DOI 10.1007/s00277-020-04149-5 PMID 32613281 6 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

Allogeneic hematopoietic stem cell transplantation for primary myelofibrosis: A single-center experience

Journal of Clinical Oncology, 2020

DOI 10.1200/jco.2020.38.15_suppl.e19522 Source : ORCID

Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Blood, 2020

DOI 10.1182/blood-2020-135874 50 citations (OpenAlex) Source : ORCID

Are Autologous Stem Cell Transplants Still Required to Treat Myeloma in the Era of Novel Therapies? A Review from the Chronic Malignancies Working Party of the EBMT

Biology of Blood and Marrow Transplantation, 2020

DOI 10.1016/j.bbmt.2020.04.016 PMID 32417491 8 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

The Lancet Haematology, 2020

DOI 10.1016/s2352-3026(20)30099-5 PMID 32359506 306 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

Clinical features associated with COVID-19 outcome in MM: First results from International Myeloma Society COVID-19 dataset

medRxiv, 2020

DOI 10.1101/2020.08.24.20177576 1 citation (Europe PMC) Texte intégral en libre accèsSource : ORCID

Clinical features associated with COVID-19 outcome in multiple myeloma: First results from the International Myeloma Society data set

Blood, 2020

DOI 10.1182/blood.2020008150 PMID 33367546 162 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

Comparison of Two Alkylating Agents Among Refractory Multiple Myeloma: Published and Our Retrospective Bendamustine Combination Experience with Melflufen As Single Agent

Blood, 2020

DOI 10.1182/blood-2020-137486 Source : ORCID

Conditioning with Bortezomib-MEL200 in Comparison to MEL200 Improves Survival Among Myeloma Patients IN≤PR Prior to Auto-HCT: A Study from the CMWP of the EBMT

Bone Marrow Transplantation, 2020

Source : ORCID

Consolidation Treatment with VRD Followed By Maintenance Therapy Versus Maintenance Alone in Newly Diagnosed, Transplant-Eligible Patients with Multiple Myeloma (MM): A Randomized Phase 3 Trial of the European Myeloma Network (EMN02/HO95)

Blood, 2020

DOI 10.1182/blood-2020-139337 5 citations (OpenAlex) Source : ORCID

Daratumumab after Allogeneic Hematopoietic Stem Cell Transplantation in Multiple Myeloma: Safety and Efficacy. a Retrospective Study from the Cmwp EBMT

Blood, 2020

DOI 10.1182/blood-2020-138478 Source : ORCID

Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)

Leukemia, 2020

DOI 10.1038/s41375-020-0718-z PMID 32024950 79 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: Subgroup analysis of CASTOR based on cytogenetic risk

Journal of Hematology and Oncology, 2020

DOI 10.1186/s13045-020-00948-5 PMID 32819447 36 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

Dihydroartemisinin Induces Growth Arrest and Overcomes Dexamethasone Resistance in Multiple Myeloma

Frontiers in Oncology, 2020

DOI 10.3389/fonc.2020.00767 PMID 32500030 17 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

Drug Targeting of Genomic Instability in Multiple Myeloma

Frontiers in Genetics, 2020

DOI 10.3389/fgene.2020.00228 PMID 32373151 21 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

Effect of Cyclophosphamide on Hemorrhagic Cystitis Following Haploidentical Related Compared to Matched Related/Unrelated Donor Hematopoietic Stem Cell Transplantation: A 7-Year Tertiary Center Analysis

Biology of Blood and Marrow Transplantation, 2020

DOI 10.1016/j.bbmt.2019.12.617 Texte intégral en libre accèsSource : ORCID

Effects of ABO incompatibility in allogeneic hematopoietic stem cell transplantation,Effets de l'incompatibilité ABO pour l'allogreffe de cellules souches hématopoïétiques

Transfusion Clinique et Biologique, 2020

DOI 10.1016/j.tracli.2020.06.008 PMID 32659269 10 citations (Europe PMC) Source : ORCID

Efficacy and Safety of Carfilzomib, Dexamethasone, Daratumumab (KdD) Twice-Weekly at 56 mg/m2 and Once-Weekly at 70 mg/m2 in Relapsed or Refractory Multiple Myeloma (RRMM): Cross-Study Comparison of the CANDOR and EQUULEUS studies

Clinical Lymphoma Myeloma and Leukemia, 2020

Source : ORCID

Efficacy and Safety of the Panobinostat-Bortezomib-Dexamethasone Combination in Relapsed or Relapsed/Refractory Multiple Myeloma: Results from the Randomized Panorama 3 Study

Blood, 2020

DOI 10.1182/blood-2020-140697 4 citations (OpenAlex) Source : ORCID

Efficacy and safety of carfilzomib, dexamethasone, daratumumab (KdD) twice-weekly at 56 mg/m2 and once-weekly at 70 mg/m2 in relapsed or refractory multiple myeloma (RRMM): Cross-study comparison of candor and MMY1001

Journal of Clinical Oncology, 2020

DOI 10.1200/jco.2020.38.15_suppl.8526 Source : ORCID

Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study

Blood Cancer Journal, 2020

DOI 10.1038/s41408-020-00357-4 PMID 32887873 110 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

Flamsa-based High-dose Sequential Conditioning Regimen followed by Allogeneic Hematopoietic Stem Cell Transplantation(ALLO-HSCT): Is It Effective in Patients with Primary Refractory or Relapsed Acute Leukemia?

Bone Marrow Transplantation, 2020

Source : ORCID

Health-Related Quality of Life in Patients with AL Amyloidosis Treated with Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone: Results from the Phase 3 Andromeda Study

Blood, 2020

DOI 10.1182/blood-2020-139438 7 citations (OpenAlex) Source : ORCID

Isatuximab for the treatment of relapsed/refractory multiple myeloma

Expert Opinion on Biological Therapy, 2020

DOI 10.1080/14712598.2021.1841747 PMID 33111607 33 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

Ixazomib as postinduction maintenance for patients with newly diagnosed multiple myeloma not undergoing autologous stem cell transplantation: The phase III TOURMALINE-MM4 trial

Journal of Clinical Oncology, 2020

DOI 10.1200/jco.20.02060 PMID 33021870 64 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

Ixazomib vs placebo maintenance for newly diagnosed multiple myeloma (NDMM) patients not undergoing autologous stem cell transplant (ASCT): The phase III TOURMALINE-MM4 trial

Journal of Clinical Oncology, 2020

DOI 10.1200/jco.2020.38.15_suppl.8527 5 citations (OpenAlex) Source : ORCID

KIR Genotype and KIR Ligand Phenotypes That Improve the in Vitro Cord Blood or Autologous NK Cell Mediated Cytotoxicity Against Myeloma Marrow Plasma Cells

Biology of Blood and Marrow Transplantation, 2020

DOI 10.1016/j.bbmt.2019.12.395 Texte intégral en libre accèsSource : ORCID

Large Granular Lymphocytosis and Its Impact on Long Term Clinical Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: 14-Year Follow-up Data

Biology of Blood and Marrow Transplantation, 2020

DOI 10.1016/j.bbmt.2019.12.405 1 citation (OpenAlex) Texte intégral en libre accèsSource : ORCID

Pomalidomide, bortezomib, and dexamethasone (PVd) in lenalidomide (LEN)-pretreated relapsed refractory multiple myeloma: Subanalysis of patients with renal impairment in OPTIMISMM

Journal of Clinical Oncology, 2020

DOI 10.1200/jco.2020.38.15_suppl.e20562 2 citations (OpenAlex) Source : ORCID

Post-Transplant Cyclophosphamide for Graft Vs Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison By Donor Type; A Study from the Chronic Malignancies Working Party of the EBMT

Blood, 2020

DOI 10.1182/blood-2020-137789 1 citation (OpenAlex) Texte intégral en libre accèsSource : ORCID

Prognostic scoring system after transplantation in myeloma: predicting early relapse

British Journal of Haematology, 2020

DOI 10.1111/bjh.16986 PMID 32712969 3 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

Reduction in Absolute Involved Free Light Chain and Difference between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving Bortezomib, Cyclophosphamide, and Dexamethasone with or without Daratumumab: Results from Andromeda

Blood, 2020

DOI 10.1182/blood-2020-137582 16 citations (OpenAlex) Source : ORCID

Role of Chimerism and flow-cytometric Monitoring of Measurable Residual Disease(MRD) after Allogeneic Hematopoietic Stem Cell Transplantation(Allo-HSCT) in Predicting Relapse in Acute Myeloid Leukemia(AML)

Bone Marrow Transplantation, 2020

Source : ORCID

The Influence of anti-thymocyte Globulin(ATG) on the Outcomes of Patients with AML W/wo Measurable Residual Disease(MRD) at the time of Unrelated Donor Transplantation

Bone Marrow Transplantation, 2020

Source : ORCID

Thyroid dysfunctions in adult patients after allogeneic hematopoietic stem cell transplantation

Clinical Transplantation, 2020

DOI 10.1111/ctr.14049 PMID 32713042 5 citations (Europe PMC) Source : ORCID

Treatment of Thrombocytopenia after Allogeneic Stem Cell Transplantation with Eltrombopag

Bone Marrow Transplantation, 2020

Source : ORCID

Upfront Autologous Hematopoietic Stem-Cell Transplantation Improves Overall Survival in Comparison with Bortezomib-Based Intensification Therapy in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the Randomized Phase 3 EMN02/HO95 Study

Blood, 2020

DOI 10.1182/blood-2020-137575 21 citations (OpenAlex) Source : ORCID

β-catenin mutations in acute myeloid leukemia

The Egyptian Journal of Haematology, 2020

DOI 10.4103/ejh.ejh_54_19 1 citation (OpenAlex) Source : ORCID